NEWARK, DE--(Marketwired - June 17, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, amended its multiproduct license and collaboration agreement with Brazil's Bio-Manguinhos/Fiocruz and the Fraunhofer USA Center for Molecular Biotechnology to enable expansion of joint work on an iBioLaunch™-produced recombinant yellow fever vaccine and other products.
Yellow fever vaccine candidates based on iBio's proprietary technology, including virus-like particles (VLPs) and traditional antigen formulations, have been highly successful in rodent virus-challenge studies. Additional tasks to be performed include non-human primate studies, the completion of IND-enabling tests, and the establishment of a commercial technology transfer program to enable Bio-Manguinhos to produce a recombinant iBioLaunch-based yellow fever vaccine in the new facility designed for that purpose that the Brazilian government has committed to build in northern Brazil.
Bio-Manguinhos/Fiocruz, the leading producer of yellow fever vaccines for worldwide use, is recognized internationally as a manufacturer of immunobiologicals for public health needs. Earlier this year, Sanofi Pasteur announced a potential yellow fever vaccine shortage for travelers due to a production problem with its own chicken egg-produced vaccine product.
Robert Erwin, iBio's president, commented: "The objective of our collaborative yellow fever vaccine development program is to enable Bio-Manguinhos to replace the current vaccine it produces in chicken eggs from a live, attenuated strain of the yellow fever virus, with a safe, low-cost, scalable recombinant vaccine produced in green plants with iBioLaunch technology."
The royalty-bearing license granted by iBio covers the nations of Latin America, the Caribbean and Africa. iBio retains the right to sell the products developed under the license and collaboration agreement in any other territory with a royalty back to Bio-Manguinhos/Fiocruz.
About iBio, Inc.
iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. In 2013, iBio established a subsidiary company in Brazil to accelerate development and commercialization of biosimilar therapeutic products.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production.
iBio uses its proprietary technology for its own innovative product portfolio including advancement of a potentially breakthrough biotherapeutic product against otherwise unstoppable fibrotic diseases such as idiopathic pulmonary fibrosis and systemic sclerosis. Further information is available at: www.ibioinc.com.
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.